MPDL3280A for Non-Small Cell Lung Cancer

Roy S. Herbst, MD, PhD
Published Online: June 12, 2013


Roy S. Herbst, MD, PhD, a professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer (NSCLC).

Herbst presented data on MPDL3280A, which targets PD-L1. This agent produced a 21% response rate for patients with multiple solid tumors, including NSCLC, and had an acceptable toxicity profile.

These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC. Herbst says researchers and physicians now have new avenues for the treatment of this disease.

Clinical Pearls



  • MPDL3280A produced a 21% response rate for patients with multiple solid tumors, including NSCLC
  • MPDL3280A had an acceptable toxicity profile, with only a few patients having immune-related events
  • These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC


<<< View all coverage from the 2013 ASCO Meeting

Related Articles
A handful of angiogenesis biomarkers predicted improved progression-free survival (PFS) and overall survival (OS) in patients with nonsquamous non-small cell lung cancer (NSCLC) treated with bevacizumab.
Eighty-five percent of patients with EGFR-positive non-small cell lung cancer (NSCLC) experienced significant reduction in tumor growth rate with the addition of cabozantinib to erlotinib.
Treatment for non-small cell lung cancer (NSCLC)—which includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma—has traditionally consisted of surgery, chemotherapy, and radiation therapy.
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer (NSCLC).
JTT Articles
The Transformation of Treatment in CLL: A Q & A With Dr. William G. Wierda
Tailoring Treatments in HER2-Positive Breast Cancer
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.